Tag: ADMA Biologics
July 8, 2019
ADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM® and Nabi-HB®
ADMA Biologics NASDAQ:ADMA) has announced that the US Food and Drug Administration (FDA) has revoked the licenses for BIVIGAM and... April 17, 2019
ADMA Biologics Granted US Patent for Treatment and Prevention of Pneumococcal Infections
ADMA Biologics (NASDAQ:ADMA) has announced it has been granted patent no. 10,259,865 from the US Patent and Trademark Office for...
December 24, 2018
Pharma Outlook 2019: Drug Pricing Dialogue Continues
During this challenging time in healthcare news, our pharma outlook aims to help investors steer through the industry. December 20, 2018
ADMA Biologics Provides Regulatory Update on BIVIGAM PAS Submissions
ADMA Biologics (NASDAQ:ADMA) a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics... October 11, 2018
ADMA Biologics Provides Regulatory Update for BIVIGAM
ADMA Biologics (NASDAQ:ADMA) a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics... October 3, 2018
ADMA BioCenters Receives FDA Approval for Third Plasma Collection Center
ADMA Biologics (NASDAQ:ADMA) a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment... July 26, 2018